David E. Gloriam

David E. Gloriam

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

David E. Gloriam

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2017 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
AHAlexander S. Hauser
Alexander S. Hauser
MAMisty M. Attwood
Misty M. Attwood
MRMathias Rask-Andersen
Mathias Rask-Andersen
HSHelgi B. Schiöth
Helgi B. Schiöth
DGDavid E. Gloriam
David E. Gloriam

1 January 2018 in Cell
Verified
Journal Article
Open access
AHAlexander S. Hauser
Alexander S. Hauser
SCSreenivas Chavali
Sreenivas Chavali
IMIkuo Masuho
Ikuo Masuho
LJLeonie J. Jahn
Leonie J. Jahn
KMKirill A. Martemyanov
Kirill A. Martemyanov
MBM. Madan Babu
M. Madan Babu
Natural genetic variation in the human genome is a cause of individual differences in responses to medications and is an underappreciated burden on public health. Although 108 G-protein-coupled receptors (GPCRs) are the targets of 475 (∼34%) Food and Drug Administration (FDA)-approved drugs and account for a global sales volume of over 180 billion US dollars annually, the prevalence of genetic variation among GPCRs targeted by drugs is unknown. By analyzing data from 68,496 individuals, we find that GPCRs targeted by drugs show genetic variation within functional regions such as drug- and effector-binding sites in the human population. We experimentally show that certain variants of μ-opioid and Cholecystokinin-A receptors could lead to altered or adverse drug response. By analyzing UK National Health Service drug prescription and sales data, we suggest that characterizing GPCR variants could increase prescription precision, improving patients' quality of life, and relieve the economic and societal burden due to variable drug responsiveness. VIDEO

16 November 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
GPGáspár Pándy-Szekeres
Gáspár Pándy-Szekeres
CMChristian Munk
Christian Munk
TTTsonko M Tsonkov
Tsonko M Tsonkov
MSMordalski Stefan
Mordalski Stefan
KHKasper Harpsøe
Kasper Harpsøe
DGDavid E Gloriam
David E Gloriam
G protein-coupled receptors are the most abundant mediators of both human signalling processes and therapeutic effects. Herein, we report GPCRome-wide homology models of unprecedented quality, and roughly 150 000 GPCR ligands with data on biological activities and commercial availability. Based on the strategy of ‘Less model – more Xtal’, each model exploits both a main template and alternative local templates. This achieved higher similarity to new structures than any of the existing resources, and refined crystal structures with missing or distorted regions. Models are provided for inactive, intermediate and active states—except for classes C and F that so far only have inactive templates. The ligand database has separate browsers for: (i) target selection by receptor, family or class, (ii) ligand filtering based on cross-experiment activities (min, max and mean) or chemical properties, (iii) ligand source data and (iv) commercial availability. SMILES structures and activity spreadsheets can be downloaded for further processing. Furthermore, three recent landmark publications on GPCR drugs, G protein selectivity and genetic variants have been accompanied with resources that now let readers view and analyse the findings themselves in GPCRdb. Altogether, this update will enable scientific investigation for the wider GPCR community. GPCRdb is available at http://www.gpcrdb.org.

1 January 2015 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
VIVignir Isberg
Vignir Isberg
CGChris De Graaf
Chris De Graaf
ABAndrea Bortolato
Andrea Bortolato
VCVadim Cherezov
Vadim Cherezov
Vsevolod KatritchVsevolod Katritch
Vsevolod Katritch
DGDavid E. Gloriam
David E. Gloriam

10 May 2017 in Nature
Verified
Journal Article
Closed access
PDF file
TFTilman Flock
Tilman Flock
AHAlexander S. Hauser
Alexander S. Hauser
NLNadia Lund
Nadia Lund
DGDavid E. Gloriam
David E. Gloriam
SBSanthanam Balaji
Santhanam Balaji
MBM. Madan Babu
M. Madan Babu

1 September 2006 in Genomics
Verified
Journal Article
Closed access
TBThóra K. Bjarnadóttir
Thóra K. Bjarnadóttir
DGDavid E. Gloriam
David E. Gloriam
SHSofia H. Hellstrand
Sofia H. Hellstrand
HKHelena Kristiansson
Helena Kristiansson
RFRobert Fredriksson
Robert Fredriksson
HSHelgi B. Schiöth
Helgi B. Schiöth